X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-23 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $61.92 | -15,000 | 772,571 | -2% | -$928,845 | |||||
2024-04-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $30.12 | -2,174 | 176,206 | -1% | -$65,483 | ||||||
2024-04-22 | ZURA | Zura Bio Ltd | Howell Michael | See Remarks | P - Purchase | $3.13 | +7,987 | 122,382 | +7% | +$24,999 | ||||||
2024-04-22 | ZURA | Zura Bio Ltd | Nistala Kiran | EVP | P - Purchase | $3.13 | +3,195 | 3,195 | New | +$10,000 | ||||||
2024-04-22 | ZURA | Zura Bio Ltd | Munshi Amit | Dir | P - Purchase | $3.13 | +159,744 | 777,384 | +26% | +$499,999 | ||||||
2024-04-22 | ZURA | Zura Bio Ltd | Sidhu Someit | Dir | P - Purchase | $3.13 | +1,186,901 | 3,675,047 | +48% | +$3,715,000 | ||||||
2024-04-22 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $3.10 | -5,000 | 390,092 | -1% | -$15,490 | ||||||
| AD | 2024-04-19 | INMB | Inmune Bio, Inc. | Moss David J | CFO, Treasurer, Secretary, 10% | P - Purchase | $8.32 | +18,028 | 1,268,179 | +1% | +$149,993 | |||||
| AD | 2024-04-19 | INMB | Inmune Bio, Inc. | Tesi Raymond Joseph | Pres, CEO, 10% | P - Purchase | $8.32 | +18,028 | 1,538,726 | +1% | +$149,993 | |||||
| AD | 2024-04-19 | INMB | Inmune Bio, Inc. | Lowdell Mark William | Chief Scientific Officer, 10% | P - Purchase | $8.32 | +14,423 | 1,510,806 | +1% | +$119,999 | |||||
| AD | 2024-04-19 | INMB | Inmune Bio, Inc. | Juda Scott | Dir | P - Purchase | $8.32 | +29,603 | 66,603 | +80% | +$246,297 | |||||
| M | 2024-04-19 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.90 | +21,528 | 1,107,807 | +2% | +$19,421 | |||||
| M | 2024-04-19 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.75 | -953 | 77,619 | -1% | -$715 | |||||
| M | 2024-04-19 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.75 | -1,383 | 512,026 | 0% | -$1,038 | |||||
2024-04-19 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.75 | -9,601 | 802,935 | -1% | -$7,207 | ||||||
| M | 2024-04-19 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.75 | -3,378 | 17,812,862 | 0% | -$2,534 | |||||
| M | 2024-04-18 | PROK | Prokidney Corp. | Weber Darin J. | SVP of Regulatory Development | S - Sale | $2.51 | -17,238 | 155,194 | -10% | -$43,343 | |||||
| DM | 2024-04-19 | FENC | Fennec Pharmaceuticals Inc. | Haigh Adrian | COO | S - Sale+OE | $9.33 | -44,445 | 0 | -100% | -$414,472 | |||||
| D | 2024-04-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $61.27 | -8,000 | 95,679 | -8% | -$490,199 | |||||
2024-04-17 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $103.38 | -15,000 | 11,722,969 | 0% | -$1,550,703 | ||||||
2024-04-17 | IMVT | Immunovant, Inc. | Levine Mark S. | GC | S - Sale | $29.06 | -9,827 | 347,119 | -3% | -$285,554 | ||||||
2024-04-17 | IMVT | Immunovant, Inc. | Macias William L. | Chief Medical Officer | S - Sale | $29.06 | -8,280 | 377,650 | -2% | -$240,602 | ||||||
2024-04-17 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $29.06 | -12,253 | 359,456 | -3% | -$356,049 | ||||||
2024-04-17 | IMVT | Immunovant, Inc. | Butchko Julia G. | Chief Development Officer | S - Sale | $29.06 | -10,115 | 451,627 | -2% | -$293,923 | ||||||
2024-04-17 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $29.06 | -34,079 | 1,052,879 | -3% | -$990,269 | ||||||
2024-04-19 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.37 | +2,750 | 558,697 | 0% | +$1,013 | ||||||
| DM | 2024-04-17 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $45.53 | -35,000 | 195,307 | -15% | -$1,593,550 | |||||
| DM | 2024-04-17 | FENC | Fennec Pharmaceuticals Inc. | Haigh Adrian | COO | S - Sale+OE | $6.04 | -88,888 | 0 | -100% | -$536,661 | |||||
| D | 2024-04-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $25.74 | -1,750 | 1,737 | -50% | -$45,045 | |||||
2024-04-16 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $7.66 | -11,447 | 7,229,861 | 0% | -$87,725 | ||||||
| DM | 2024-04-16 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $7.63 | -48,124 | 1,231,055 | -4% | -$367,007 | |||||
| D | 2024-04-16 | ACLX | Arcellx, Inc. | Ware Olivia C | Dir | S - Sale+OE | $55.55 | -9,402 | 0 | -100% | -$522,260 | |||||
| D | 2024-04-15 | OTLK | Outlook Therapeutics, Inc. | Syntone Ventures LLC | 10% | P - Purchase | $0.00 | +714,286 | 1,705,438 | +72% | +$0 | |||||
| DM | 2024-04-16 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $38.42 | -20,000 | 168,176 | -11% | -$768,390 | |||||
2024-04-16 | PROK | Prokidney Corp. | Weber Darin J. | SVP of Regulatory Development | S - Sale | $2.50 | -17,238 | 172,432 | -9% | -$43,095 | ||||||
| D | 2024-04-15 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $59.91 | -19,582 | 408,122 | -5% | -$1,173,232 | |||||
| D | 2024-04-15 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $133.37 | -19,818 | 40,778 | -33% | -$2,643,020 | |||||
2024-04-15 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $18.29 | -1,666 | 118,043 | -1% | -$30,471 | ||||||
| D | 2024-04-15 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $18.19 | -15,000 | 408,035 | -4% | -$272,871 | |||||
| A | 2024-04-04 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $15.50 | +193,548 | 616,541 | +46% | +$2,999,994 | |||||
| A | 2024-04-04 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $15.50 | +193,548 | 616,541 | +46% | +$2,999,994 | |||||
| DM | 2024-04-15 | FENC | Fennec Pharmaceuticals Inc. | Haigh Adrian | COO | S - Sale+OE | $6.30 | -88,888 | 0 | -100% | -$559,848 | |||||
| M | 2024-04-01 | PROK | Prokidney Corp. | Weber Darin J. | SVP of Regulatory Development | S - Sale | $1.73 | -84,403 | 189,670 | -31% | -$146,005 | |||||
2024-04-15 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale | $105.02 | -15,000 | 1,642,290 | -1% | -$1,575,300 | ||||||
| D | 2024-04-15 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $10.45 | -800 | 45,838 | -2% | -$8,360 | |||||
2024-04-10 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $35.40 | -17,500 | 810,850 | -2% | -$619,467 | ||||||
2024-04-10 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $107.12 | -15,000 | 11,737,969 | 0% | -$1,606,865 | ||||||
| D | 2024-04-10 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $37.00 | -2,155 | 15,700 | -12% | -$79,735 | |||||
| M | 2024-04-09 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.88 | +3,188 | 1,086,279 | 0% | +$2,805 | |||||
2024-04-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $33.16 | -556 | 74,444 | -1% | -$18,434 | ||||||
2024-04-09 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $31.18 | -3,689 | 371,709 | -1% | -$115,023 | ||||||
2024-04-09 | IMVT | Immunovant, Inc. | Butchko Julia G. | Chief Development Officer | S - Sale | $31.18 | -1,053 | 461,742 | 0% | -$32,833 | ||||||
2024-04-09 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $31.18 | -4,807 | 1,086,958 | 0% | -$149,882 | ||||||
| A | 2024-01-29 | CGON | Cg Oncology, Inc. | Decheng Capital Global Life Sciences Fund Iv, L.P. | 10% | P - Purchase | $19.00 | +400,000 | 4,958,810 | +9% | +$7,600,000 | |||||
| D | 2024-04-08 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $101.93 | -705 | 5,048 | -12% | -$71,859 | |||||
| D | 2024-04-04 | SRZN | Surrozen, Inc./De | Williams Charles O | CFO, COO | P - Purchase | $0.00 | +1,474 | 1,474 | New | +$0 | |||||
| D | 2024-04-04 | SRZN | Surrozen, Inc./De | Parker Craig C | CEO | P - Purchase | $0.00 | +1,474 | 1,474 | New | +$0 | |||||
| D | 2024-04-04 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $15.50 | +193,548 | 627,652 | +45% | +$2,999,994 | |||||
| D | 2024-04-04 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $15.50 | +193,548 | 627,652 | +45% | +$2,999,994 | |||||
2024-04-04 | HLVX | Hillevax, Inc. | Frazier Life Sciences X, L.P. | 10% | P - Purchase | $14.50 | +8,850 | 8,544,187 | 0% | +$128,325 | ||||||
2024-04-03 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $101.69 | -15,000 | 11,752,969 | 0% | -$1,525,268 | ||||||
| M | 2024-04-03 | HLVX | Hillevax, Inc. | Kohli Aditya | Dir | S - Sale | $14.69 | -18,000 | 789,776 | -2% | -$264,467 | |||||
| DM | 2024-04-03 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $8.93 | -130,000 | 938,524 | -12% | -$1,160,900 | |||||
| M | 2024-04-03 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.91 | +17,378 | 1,083,091 | +2% | +$15,814 | |||||
| M | 2024-04-04 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | CEO | S - Sale | $10.82 | -88,583 | 187,471 | -32% | -$958,669 | |||||
| D | 2024-04-02 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $1.05 | -51,169 | 865,079 | -6% | -$53,727 | |||||
2024-04-02 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.77 | -368 | 513,409 | 0% | -$284 | ||||||
2024-04-02 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.77 | -1,533 | 812,536 | 0% | -$1,183 | ||||||
2024-04-02 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.77 | -281 | 78,572 | 0% | -$217 | ||||||
2024-04-02 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.77 | -885 | 17,816,240 | 0% | -$683 | ||||||
2024-04-03 | VIR | Vir Biotechnology, Inc. | De Backer Marianne | CEO | S - Sale | $9.46 | -72,995 | 678,457 | -10% | -$690,365 | ||||||
2024-04-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $32.74 | -492 | 178,380 | 0% | -$16,106 | ||||||
2024-04-02 | TWST | Twist Bioscience Corp | Banyai William | See Remark | S - Sale | $32.74 | -327 | 345,986 | 0% | -$10,705 | ||||||
| D | 2024-04-02 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $32.74 | -1,132 | 514,149 | 0% | -$37,057 | |||||
2024-04-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $32.74 | -129 | 81,004 | 0% | -$4,223 | ||||||
2024-04-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $32.74 | -229 | 92,421 | 0% | -$7,497 | ||||||
2024-04-02 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale | $213.09 | -93 | 4,886 | -2% | -$19,817 | ||||||
| M | 2024-04-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $31.02 | -23,687 | 70,060 | -25% | -$734,805 | |||||
2024-04-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $32.12 | -3,401 | 104,594 | -3% | -$109,240 | ||||||
2024-04-01 | BEAM | Beam Therapeutics Inc. | Burrell Terry-Ann | CFO | S - Sale | $32.12 | -5,446 | 70,137 | -7% | -$174,926 | ||||||
| D | 2024-04-01 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale+OE | $32.13 | -18,102 | 1,161,343 | -2% | -$581,617 | |||||
| D | 2024-04-01 | BEAM | Beam Therapeutics Inc. | Ciaramella Giuseppe | Pres | S - Sale+OE | $32.12 | -4,534 | 169,616 | -3% | -$145,632 | |||||
| D | 2024-04-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $31.78 | -8,153 | 1,737 | -82% | -$259,102 | |||||
| D | 2024-04-02 | XLO | Xilio Therapeutics, Inc. | Gilead Sciences, Inc. | 10% | P - Purchase | $0.76 | +485,250 | 7,345,473 | +7% | +$368,790 | |||||
2024-04-02 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $8.82 | -11,447 | 7,241,308 | 0% | -$100,942 | ||||||
2024-04-03 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | CEO | S - Sale | $10.78 | -40,584 | 276,054 | -13% | -$437,451 | ||||||
2024-04-01 | FENC | Fennec Pharmaceuticals Inc. | Andrade Robert | CFO | P - Purchase | $0.00 | +12,500 | 104,271 | +14% | +$0 | ||||||
2024-04-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | CEO | P - Purchase | $0.00 | +29,167 | 316,638 | +10% | +$0 | ||||||
2024-04-01 | ACLX | Arcellx, Inc. | Elghandour Rami | SEE REMARKS | S - Sale | $67.09 | -23,086 | 69,253 | -25% | -$1,548,887 | ||||||
| D | 2024-04-01 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $137.30 | -272 | 7,507 | -3% | -$37,346 | |||||
| D | 2024-04-01 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $66.73 | -1,667 | 30,597 | -5% | -$111,234 | |||||
2024-04-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $66.69 | -3,000 | 218,289 | -1% | -$200,066 | ||||||
2024-04-01 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale | $66.71 | -2,616 | 625,209 | 0% | -$174,502 | ||||||
| D | 2024-04-01 | IMCR | Immunocore Holdings Plc | St Leger Tina Amber | CHRO | S - Sale+OE | $64.06 | -4,375 | 0 | -100% | -$280,263 | |||||
2024-04-02 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $9.88 | -1,357 | 117,004 | -1% | -$13,407 | ||||||
2024-04-02 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Pres, CEO | S - Sale | $9.86 | -12,115 | 322,839 | -4% | -$119,454 | ||||||
2024-04-01 | VIR | Vir Biotechnology, Inc. | Hanly Ann M. | EVP, CTO | S - Sale | $10.05 | -2,711 | 132,081 | -2% | -$27,251 | ||||||
2024-04-01 | GILD | Gilead Sciences, Inc. | Parsey Merdad | Chief Medical Officer | S - Sale | $72.96 | -2,000 | 96,304 | -2% | -$145,920 | ||||||
2024-04-01 | DNLI | Denali Therapeutics Inc. | Krognes Steve E. | Dir | S - Sale | $20.50 | -92,500 | 897,341 | -9% | -$1,896,250 | ||||||
| D | 2024-03-28 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $10.10 | -65,000 | 1,043,524 | -6% | -$656,500 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |